Press releases | Corporate and M&A |

Maxcyte Inc lists on AIM

Overview

A Travers Smith team led by corporate partner Andrew Gillen advised on Maxcyte Inc's IPO on AIM, with Panmure Gordon Limited acting as NOMAD to the company. 

MaxCyte is an established and revenue-generating U.S.-based developer and supplier of electroporation technology and instrumentation to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing, and immuno-oncology. The company's patented flow electroporation technology enables its products to deliver fast, reliable, and scalable cell engineering to a broad range of healthcare markets to drive a new generation of cell-based medicines.

Furthermore, as a US-based company admitted to trading on AIM and issuing its shares to non-US persons located outside of the United States pursuant to Regulation S under the US Securities Act of 1933, Maxcyte's shares have been made eligible for electronic settlement in accordance with the new "Category 3 securities" settlement procedures available through the CREST system operated by Euroclear UK & Ireland.

Andrew Gillen was supported by senior counsel Dan McNamee and corporate associate Ceilidh Thomson.